Gerardus Johannes Platenburg - 18 Mar 2026 Form 3 Insider Report for ProQR Therapeutics N.V. (PRQR)

Role
Chief Scientific Officer, Director
Signature
/s/ Pieter Erik de Ridders, Attorney-in-Fact
Issuer symbol
PRQR
Transactions as of
18 Mar 2026
Net transactions value
$0
Form type
3
Filing time
18 Mar 2026, 16:08:11 UTC
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Platenburg Gerardus Johannes Chief Scientific Officer, Director PROQR THERAPEUTICS N.V., ZERNIKEDREEF 9, LEIDEN, NETHERLANDS /s/ Pieter Erik de Ridders, Attorney-in-Fact 18 Mar 2026 0002115507

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding PRQR Ordinary Shares 824,388 18 Mar 2026 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding PRQR Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 61,453 $4.90 Direct F1
holding PRQR Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 71,409 $3.30 Direct F1
holding PRQR Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 17,878 $15.78 Direct F1
holding PRQR Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 141,369 $9.91 Direct F1
holding PRQR Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 79,033 $4.20 Direct F1
holding PRQR Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 77,353 $1.02 Direct F1
holding PRQR Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 172,603 $0.6700 Direct F1
holding PRQR Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 152,000 $3.41 Direct F2
holding PRQR Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 164,715 $1.98 Direct F3
holding PRQR Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 159,358 $2.65 Direct F4
holding PRQR Share Option (Right to Buy) 18 Mar 2026 Ordinary Shares 186,139 $2.02 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Fully vested.
F2 25% of the shares subject to such option vest and become exercisable on January 1, 2024, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
F3 25% of the shares subject to such option vest and become exercisable on January 1, 2025, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
F4 25% of the shares subject to such option vest and become exercisable on January 1, 2026, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
F5 25% of the shares subject to such option vest and become exercisable on January 1, 2027, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

Remarks:

Exhibit 24 - Power of Attorney